The main objective of this study is to assess the number of participants with proptosis response as of last intravenous infusion of teprotumumab.
A retrospective cohort will be followed retrospectively for endpoints at the only facility providing treatment of teprotumumab in mainland China. Eligible participants' data were collected retrospectively over a period of approximately 3 years. The target population is patients with Thyroid Eye Disease (TED) that have received teprotumumab treatment in BOAO Pilot Zone. While the primary objective is to assess the proportion of patients with proptosis response as of the last intravenous infusion of teprotumumab, the secondary objectives are to describe baseline characteristics of patients at teprotumumab initiation, and the teprotumumab use at follow-up, to describe real-world effectiveness of clinical outcomes of interest, to describe patient-reported outcomes and to describe real-world safety of teprotumumab.
Study Type
OBSERVATIONAL
Enrollment
5
Participants received teprotumumab as an intravenous (IV) infusion.
Boao Vanguard Hospital
Qionghai, Hainan, China
Number of Participants with Proptosis Response as of the Last IV Infusion Teprotumumab
Proptosis response is defined as having a ≥ 2 mm reduction in proptosis measurement from baseline in the more severely affected eye without deterioration (≥ 2 mm increase) of proptosis in the fellow eye following the last infusion.
Time frame: From baseline up to approximately 3 years
Demographics of Participants at Teprotumumab Initiation
Demographics include age in years and sex (male, female, unknown).
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Body Mass Index at Index Date
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Smoking Status
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Disease Duration
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: TED Activity
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: TED Severity
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Eye symptoms
Time frame: From baseline up to approximately 3 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Clinical Characteristics of Participants at Teprotumumab Initiation: Clinical Activity Score
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Computed Tomography (CT)/Magnetic Resonance Imaging (MRI) Measurements
Time frame: From baseline up to approximately 3 years
Clinical Characteristics of Participants at Teprotumumab Initiation: Quality of Life
Time frame: From baseline up to approximately 3 years
Number of Participants with Relevant Medical History at Teprotumumab Initiation
Medical history includes history of compressive optic neuropathy, hyperglycemia, inflammatory bowel disease (IBD), infusion reactions, and hearing impairment; therapeutic history for thyroid disease (Graves' disease or others) before teprotumumab administration; therapeutic history for TED before teprotumumab administration and complications if any; comorbidities; concomitant treatments; lab tests.
Time frame: From baseline up to approximately 3 years
Teprotumumab Use
Teprotumumab use includes dose and dosing schedule, total number of infusions and duration, dose reduction and modification (including causes), treatment interruption and causes, time interval from interruption to re-initiation, and subsequent re-initiation treatment (if any), treatment discontinuation (including causes).
Time frame: From baseline up to approximately 3 years
Proptosis Measurements of Participants
Proptosis measurements include all available proptosis measurements by eye for each participant and the change in proptosis measurement between baseline and the last infusion by eye.
Time frame: From baseline up to approximately 3 years
Clinical Activity Scores (CAS) of Participants
CAS will include all available measures of CAS items by eye for each participant and the number of participants achieving CAS value of 0 or 1 as of the last infusion among patients with active TED at baseline.
Time frame: From baseline up to approximately 3 years
Overall Response as of the Last Infusion Among Participants with Active TED
Overall response is defined as having ≥ 2-point reduction in CAS AND ≥ 2 mm reduction in proptosis from baseline in the most severely affected eye, provided there is no corresponding deterioration (≥ 2-point increase in CAS or ≥ 2 mm increase in proptosis) in the fellow eye following the last infusion. Active TED is defined as CAS≥3 on a 7-point scale at baseline.
Time frame: From baseline up to approximately 3 years
Diplopia Measurements for Participants
Diplopia measurements will include all available measures of diplopia for each participant, the binocular diplopia response as of the last infusion defined as having baseline binocular diplopia grade \> 0 and a reduction of ≥ 1 grade between baseline and the last infusion, and complete diplopia response defined as having baseline binocular diplopia grade \> 0 and achieving grade of 0 as of the last infusion.
Time frame: From baseline up to approximately 3 years
Quality of Life (QoL) as Reported by Participants
All available participant-reported QoL for each participant, overall and at subscale level, and the change in QoL between baseline and the last infusion, overall and at subscale level.
Time frame: From baseline up to approximately 3 years
Incidence of Adverse Events (AEs)
The incidence of AEs between the administration of the first dose and 30 days after the last dose of teprotumumab, including: * Any AE * Specific AEs, inclusive of infusion-related reactions, hyperglycemia, hearing impairment, and new onset or exacerbation of IBD * Serious adverse event (SAE) * AE leading to treatment discontinuation * AE leading to death.
Time frame: From baseline up to approximately 3 years
Status of Specific AEs up to 6 Months After Last Infusion of Teprotumumab
Specific AEs include infusion-related reactions, hyperglycemia, hearing impairment, and new onset or exacerbation of IBD.
Time frame: From baseline up to approximately 3 years